Notice: This company has been marked as potentially delisted and may not be actively trading. Xyratex (XRTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesShort InterestTrends XRTX vs. ATHE, PRPH, FLGC, SPRB, NERV, GLYC, NRXP, TRAW, CARA, and ACXPShould you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Alterity Therapeutics (ATHE), ProPhase Labs (PRPH), Flora Growth (FLGC), Spruce Biosciences (SPRB), Minerva Neurosciences (NERV), GlycoMimetics (GLYC), NRx Pharmaceuticals (NRXP), Traws Pharma (TRAW), Cara Therapeutics (CARA), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical preparations" industry. Xyratex vs. Alterity Therapeutics ProPhase Labs Flora Growth Spruce Biosciences Minerva Neurosciences GlycoMimetics NRx Pharmaceuticals Traws Pharma Cara Therapeutics Acurx Pharmaceuticals Alterity Therapeutics (NASDAQ:ATHE) and Xyratex (NASDAQ:XRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, community ranking, profitability, earnings, risk, analyst recommendations and media sentiment. Is ATHE or XRTX more profitable? Alterity Therapeutics' return on equity of 0.00% beat Xyratex's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Xyratex N/A -146.27%-86.83% Does the media prefer ATHE or XRTX? In the previous week, Alterity Therapeutics had 1 more articles in the media than Xyratex. MarketBeat recorded 1 mentions for Alterity Therapeutics and 0 mentions for Xyratex. Xyratex's average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.45 indicating that Xyratex is being referred to more favorably in the news media. Company Overall Sentiment Alterity Therapeutics Neutral Xyratex Neutral Which has better earnings & valuation, ATHE or XRTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AXyratexN/AN/A-$2.16M-$0.96-1.14 Do insiders and institutionals have more ownership in ATHE or XRTX? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Xyratex shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Xyratex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community prefer ATHE or XRTX? Xyratex received 152 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Alterity Therapeutics an outperform vote while only 63.41% of users gave Xyratex an outperform vote. CompanyUnderperformOutperformAlterity TherapeuticsOutperform Votes466.67% Underperform Votes233.33% XyratexOutperform Votes15663.41% Underperform Votes9036.59% Which has more risk & volatility, ATHE or XRTX? Alterity Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Xyratex has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Do analysts recommend ATHE or XRTX? Alterity Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 172.73%. Xyratex has a consensus price target of $14.00, suggesting a potential upside of 1,184.40%. Given Xyratex's higher probable upside, analysts plainly believe Xyratex is more favorable than Alterity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Xyratex 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAlterity Therapeutics beats Xyratex on 8 of the 12 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Xyratex News Delivered to You Automatically Sign up to receive the latest news and ratings for XRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XRTX vs. The Competition Export to ExcelMetricXyratexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.79M$6.57B$5.14B$9.08BDividend YieldN/A2.99%5.09%4.23%P/E Ratio-1.1410.5990.1317.19Price / SalesN/A196.061,116.25117.05Price / CashN/A57.1643.1037.85Price / Book0.475.094.784.78Net Income-$2.16M$151.83M$120.31M$225.60M Xyratex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XRTXXyratex2.5426 of 5 stars$1.09-2.7%$14.00+1,184.4%-51.3%$3.79MN/A-1.14N/AATHEAlterity Therapeutics2.5356 of 5 stars$2.31-3.8%$6.00+159.7%-15.4%$16.86MN/A0.0010News CoveragePRPHProPhase Labs3.1956 of 5 stars$0.69+5.4%$11.00+1,503.5%-86.8%$16.38M$12.75M-0.57130High Trading VolumeFLGCFlora Growth2.9322 of 5 stars$1.22-6.2%$5.00+309.8%-21.6%$16.31M$64.15M0.00280Positive NewsGap DownHigh Trading VolumeSPRBSpruce Biosciences3.8191 of 5 stars$0.39+1.4%$3.90+903.3%-80.5%$16.05M$10.09M-0.4120Analyst RevisionNERVMinerva Neurosciences3.4724 of 5 stars$2.24+1.4%$5.00+123.2%-67.0%$15.66MN/A-5.029Analyst ForecastNews CoverageGap DownGLYCGlycoMimetics4.2365 of 5 stars$0.24+0.5%$10.00+4,068.4%-89.0%$15.47M$10,000.000.0050News CoverageGap DownNRXPNRx Pharmaceuticals3.3017 of 5 stars$1.20flat$32.00+2,566.7%-96.5%$14.51MN/A-0.562News CoveragePositive NewsTRAWTraws PharmaN/A$4.70+1.1%N/AN/A$14.24M$230,000.000.0017Positive NewsGap UpCARACara Therapeutics4.2364 of 5 stars$0.26-1.5%$2.32+799.2%-29.0%$14.15M$8.69M-0.1555News CoverageGap DownACXPAcurx Pharmaceuticals1.3797 of 5 stars$0.83-3.5%$12.00+1,354.5%-77.0%$13.94MN/A-0.783Gap Up Related Companies and Tools Related Companies ATHE Alternatives PRPH Alternatives FLGC Alternatives SPRB Alternatives NERV Alternatives GLYC Alternatives NRXP Alternatives TRAW Alternatives CARA Alternatives ACXP Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XRTX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xyratex Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Xyratex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
